NRXP
NRX Pharmaceuticals, Inc.
+0.10 (+2.99%)3.45USD383K成交股數149M市值–本益比(近四季)44.0股價營收比–營收年增(近四季)2026-11-12下次財報
財報 SEC XBRL 申報值 · 美元 · 財年於 12 月結束
逐季數字是 10-Q 的單季值;財年第四季 XBRL 只有年度值,這裡用年度減前三季推算。年增率比的是去年同一會計季。
營收與利潤率近 16 季
稀釋 EPS近 16 季 · 美元
現金流近 16 季
股東回饋近 16 季 · 庫藏股與股利
損益表 逐季 · 最新在左 · 小字是年增率
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營收 | 1.1M | 1.1M | 983K | 242K | 0.00 | 0.00 | 0.00 | – | – | – | – | – |
| 營業成本 | 675K | 631K | 408K | 97K | 0.00 | 0.00 | 0.00 | – | – | – | – | – |
| 毛利 | 426K | 437K | 575K | 145K | 0.00 | 0.00 | 0.00 | – | – | – | – | – |
| 毛利率 | 38.7% | 40.9% | 58.5% | 59.9% | – | – | – | – | – | – | – | – |
| 研發費用 | 2.1M | 1.3M | 557K | 1.4M | 987K | 804K | 611K | 2.8M | 1.7M | 5.4M | 3.3M | 3.9M |
| 銷售管理費用 | 4.7M | 3.8M | 4.6M | 2.8M | 2.7M | 2.9M | 2.4M | 4.2M | 4.3M | 4.7M | 2.5M | 4.1M |
| 營業利益 | −6.5M+74% | −4.7M+23% | −4.6M+53% | −4.0M-43% | −3.7M-38% | −3.8M-62% | −3.0M-48% | −7.1M-14% | −6.0M | −10.0M | −5.8M | −8.2M |
| 營業利益率 | -590.8% | -444.0% | -470.3% | -1,662.8% | – | – | – | – | – | – | – | – |
| 稅後淨利 | −16.5M-6% | −1.4M-74% | 361K-122% | −5.9M-25% | −17.6M+169% | −5.5M-44% | −1.6M-73% | −7.9M-9% | −6.5M | −9.9M | −6.1M | −8.7M |
| 淨利率 | -1,500.5% | -133.9% | 36.7% | -2,433.9% | – | – | – | – | – | – | – | – |
| 稀釋 EPS | – | – | – | – | – | – | – | – | -0.74 | – | -0.07 | -0.12 |
| 稀釋股數 | – | – | – | – | – | – | – | – | 8.9M | – | 81.9M | 73.2M |
資產負債表 期末餘額
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 現金與約當現金 | 26.7M | 6.7M | 7.8M | 7.2M | 2.9M | 5.5M | 1.6M | 1.9M | 1.3M | 4.6M | 8.9M | 15.0M |
| 應收帳款 | 206K | 181K | 161K | 239K | – | – | – | – | – | – | – | – |
| 存貨 | – | – | – | – | – | – | – | – | – | – | – | – |
| 總資產 | 34.2M | 11.9M | 13.0M | 15.0M | 4.8M | 7.6M | 4.5M | 5.3M | 3.8M | 7.3M | 13.1M | 19.8M |
| 有息負債 | – | – | – | – | – | – | – | – | – | 9.2M | 10.1M | 12.7M |
| 總負債 | 34.3M | 25.7M | 28.9M | 40.8M | 40.5M | 32.8M | 23.3M | 23.7M | 18.9M | 19.0M | 19.3M | 22.6M |
| 股東權益 | −170K | −13.8M | −15.9M | −25.8M | −35.6M | −25.2M | −18.8M | −18.4M | −15.1M | −11.7M | −6.2M | −2.8M |
| 負債比 | 100.5% | 216.1% | 223.0% | 271.7% | 836.2% | 431.5% | 521.8% | 449.4% | 497.8% | 260.4% | 147.4% | 114.2% |
| 淨現金(現金 − 有息負債) | – | – | – | – | – | – | – | – | – | −4.6M | −1.2M | 2.3M |
現金流量表 單季
| 科目 | 26Q2 | 26Q1 | 25Q4 | 25Q3 | 25Q2 | 25Q1 | 24Q3 | 24Q2 | 24Q1 | 23Q4 | 23Q3 | 23Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 營業現金流 | – | −4.3M+23% | – | – | – | −3.5M | – | – | −3.7M | – | – | – |
| 資本支出 | – | – | – | – | – | 0.00 | – | – | 0.00 | – | – | – |
| 自由現金流 | – | – | – | – | – | −3.5M | – | – | −3.7M | – | – | – |
| 折舊攤銷 | 66K | 63K | 43K | 26K | 0.00 | 1K | 2K | – | – | – | – | – |
| 買回庫藏股 | – | – | – | – | – | – | – | – | – | – | – | – |
| 現金股利 | – | – | – | – | – | – | – | – | – | – | – | – |
| 自由現金流率 | – | – | – | – | – | – | – | – | – | – | – | – |
營收拆解 2025 年度 10-K 的分部揭露 · 年增對前一年度
產品／服務2025 年度 · 1.2M
| Therapy | 854K | 69.7% | – |
|---|---|---|---|
| Procedures | 371K | 30.3% | – |
各維度的加總不一定等於合併營收:分部有時含內部交易、地區有時只揭露主要國家。挑的是加總最接近合併營收的那個標籤。
年度 10-K
| 財年 | 營收 | 年增 | 稅後淨利 | 淨利率 | 稀釋 EPS | 自由現金流 |
|---|---|---|---|---|---|---|
| FY2025 | 1.2M | – | −28.6M | -2,336.5% | – | – |
| FY2024 | 0.00 | – | −25.1M | –% | – | −10.6M |
| FY2023 | 0.00 | – | −30.2M | –% | – | −21.7M |
| FY2023 | – | – | – | –% | – | – |
| FY2023 | – | – | – | –% | – | – |
| FY2022 | – | – | −39.8M | –% | -0.60 | −39.8M |
| FY2021 | – | – | −93.1M | –% | -1.98 | −37.7M |
| FY2020 | 139K | – | −51.8M | -37,313.0% | -1.51 | −2.3M |